Your browser doesn't support javascript.
loading
Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis.
Wu, Xian-Meng; Qian, Yong-Kang; Chen, Hua-Ling; Hu, Chen-Hua; Chen, Bing-Wei.
Afiliación
  • Wu XM; Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China.
  • Qian YK; Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China.
  • Chen HL; Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China.
  • Hu CH; Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China.
  • Chen BW; Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China.
Curr Oncol ; 30(9): 8444-8463, 2023 09 15.
Article en En | MEDLINE | ID: mdl-37754530
Despite the development of HER2-targeted drugs, achieving favorable outcomes for patients with HR+/HER2+MBC remains challenging. This study utilized Bayesian Network Meta-analysis to compare the efficacy and safety of anti-HER2 combination regimens. The primary analysis focused on progression-free survival (PFS), while secondary analyses included objective response rate, overall survival (OS) and the incidence rate of grade 3/4 adverse events (AEs). A comprehensive search across seven databases identified 25 randomized controlled trials for inclusion in this meta-analysis. For patients eligible for endocrinotherapy, our findings revealed that dual-target combined endocrine therapy, such as Her2-mAb+Her2-mAb+Endo (HR = 0.38; 95%CrI: 0.16-0.88) and Her2-mAb+Her2-tki+Endo (HR = 0.45; 95%CrI: 0.23-0.89), significantly improved PFS compared to endocrine therapy alone. According to the surface under the cumulative ranking curves (SUCRAs), Her2-mAb+Her2-mAb+Endo and Her2-mAb+Her2-tki+Endo ranked highest in terms of PFS and OS, respectively. For patients unsuitable for endocrine therapy, anti-HER2 dual-target combined chemotherapy, such as Her2-mAb+Her2-mAb+Chem (HR = 0.76; 95%CrI: 0.6-0.96) and Her2-mAb+Her2-tki+Chem (HR = 0.48; 95%CrI: 0.29-0.81), demonstrated significant improvements in PFS compared to Her2-mAb+Chem. The results were the same when compared with Her2-tki+Chem. According to the SUCRAs, Her2-mAb+Her2-tki+Chem and Her2-mAb+Her2-mAb+Chem ranked highest for PFS and OS, respectively. Subgroup analyses consistently supported these overall findings, indicating that dual-target therapy was the optimal approach irrespective of treatment line.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Female / Humans Idioma: En Revista: Curr Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Female / Humans Idioma: En Revista: Curr Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza